Nav: Home

Many elderly patients with metastatic renal cell carcinoma benefit from targeted therapies

June 20, 2019

PHILADELPHIA--Many elderly patients with metastatic renal cell carcinoma (RCC)--who are often underrepresented in clinical trials to treat the kidney cancer--are seeing overall survival benefits from treatment with targeted therapies, according to a new study from Penn Medicine researchers published this month in JAMA Network Open. Analyzing 13 years of data on Medicare patients, the study found that the patients who received targeted therapies were more medically complex than those who received the older, more toxic treatments that were available earlier in the study period, indicating that newer treatments are offering hope to more people.

Since 2005, the U.S. Food and Drug Administration has approved 12 targeted therapies for the treatment of advanced RCC. However, clinical trials investigating these therapies often exclude sicker patients and those over the age of 65, leaving a gap in knowledge about the effectiveness of newer versus older treatments in this population, especially when they are treated in routine health care settings rather than in research studies.

"Our findings suggest that targeted therapies offered new treatment options to elderly and medically complex patients who may have otherwise foregone the treatments available 15 years ago given their high toxicity and limited benefit," said senior author Jalpa A. Doshi, PhD, a professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania. "RCC is a cancer where people can often try other treatment options if the first one isn't effective, so even small gains may mean that a person might live long enough to try the next innovation. What's more, studies are showing that current treatments, including immunotherapies, are leading to even better outcomes than those that were observed during our study time frame."

Results also showed that targeted therapies offered a modest survival benefit as compared to older treatments, even though as a whole, the targeted therapy treatment group had characteristics that put them at risk for worse outcomes.

The researchers conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 2000 to 2013 to examine overall survival and estimated overall survival improvements in over 1,100 patients with stage IV clear cell RCC who received any FDA-approved targeted therapy (63 percent of patients) or nontargeted therapy (37 percent of patients). Most patients were aged 65 or older, and approximately 13 percent were younger but eligible for Medicare due to disability prior to their RCC diagnosis.

The initial analysis found no statistically significant difference in survival between targeted and nontargeted therapies. However, a more in-depth analysis that used statistical techniques to mimic the more controlled conditions found in clinical trials--known as an instrumental variable analysis--revealed a three-month survival advantage with targeted therapies compared to older treatments. Estimated overall survival improvements with targeted therapy versus nontargeted therapies were also statistically significant--eight percent at one year, seven percent at two years, and five percent at three years.

"The more sophisticated statistical methods allowed us to see an unbiased picture of how the treatments compared in the real world," said first author Pengxiang Li, PhD, a senior research investigator at Penn Medicine. "The method helped control for unmeasured differences between the treatment groups, which cannot be adjusted using traditional approaches."

Despite the findings, the median survival benefits observed in this real-world patient population were smaller compared to the benefits seen in clinical trial participants enrolled in randomized studies of targeted therapies. The combined findings underscore that research studies summarize outcomes for groups of patients and may not accurately reflect how treatments will perform in the real world or what any individual patient can expect from treatment.

For example, in this study, half of the targeted therapy group had passed away within nine months, but 10 percent of people survived longer than 47 months. Among that group with better outcomes, targeted therapies offered an 11-month survival advantage over older treatments, the researchers reported.

"Treatment decisions involve weighing potential risks, benefits, and costs of treatment as well as quality-of-life considerations, which may vary from person to person depending on their medical situation and preferences. Good communication between patients and their treatment teams is essential, and knowing more about real-world outcomes can help with those discussions," said co-author Amy R. Pettit, PhD, adjunct fellow at the Penn Center for Public Health Initiatives.

The study not only demonstrates that an older, more medically complex population has benefitted from targeted therapies, but also highlights the importance of rigorous methods to evaluate the real-world impact of treatments on health outcomes, the researchers wrote.
Co-authors include Jordan Jahnke, MS, and Yu-Ning Wong, MD, MSCE.

This study was funded by Pharmaceutical Research and Manufacturers of America.

ne is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center--which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report--Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation's first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.

University of Pennsylvania School of Medicine

Related Clinical Trials Articles:

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.
Telemedicine helps improve participation in clinical trials
Videos and creative uses of other visuals provide a novel way to obtain informed consent during clinical trials to improve participants' understanding and retention of trial information, according to a study by Nemours Children's Health System presented at the American Thoracic Society (ATS) Annual Conference.
Not enough women included in some heart disease clinical trials
Women are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome but proportionately or overrepresented in trials for hypertension, atrial fibrillation and pulmonary arterial hypertension, when compared to incidence or prevalence of women within each disease population, according to a study in the Journal of the American College of Cardiology.
BU: Obese patients underrepresented in cancer clinical trials
A new review by Boston University School of Public Health researchers found that less than one-fifth of participants in cancer-related clinical trials are obese.
Are women really under-represented in clinical trials?
Several studies have reported a lack of gender diversity in clinical trials, with trials including mostly adult males; however, a recent review of publicly available registration data of clinical trials at the US Food and Drug Administration for the most frequently prescribed drug classes found no evidence of any systemic significant under-representation of women.
More Clinical Trials News and Clinical Trials Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at